Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B7
Source: 0001140361-25-000634
Chunk: 26

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B7
Chunk 26
---
 voting and dispositive power over the shares held by him directly and the shares held by TAS. Dr. Springer disclaims beneficial ownership of the shares held by TAS. Dr. Lu exercises sole voting and dispositive power over the shares held by her directly. The principal business address of each of Dr. Springer, TAS, and Dr. Lu is 36 Woodman Road, Newton, MA, 02467. |

| (4) | Based on information known to us, and consists of (i) 4,555,260 shares of Common Stock held by the Seven One Eight Three Four Irrevocable Trust, or the Trust, and (ii) 1,880,075 shares of Common Stock underlying 56,402.254 shares of Series A Preferred Stock held by the Trust. The trustees of the Trust are Elizabeth Hoge and Sinan Kalayoglu, each of whom has shared voting and dispositive control over the shares of Common Stock and Series A Preferred Stock held by the Trust. Murat Kalayoglu, a member of our Board of Directors, has the power to remove and appoint new trustees of the Trust and, pursuant to a right of substitution, to acquire from the Trust the shares of Common Stock and Series A Preferred Stock held by the Trust in exchange for assets with an equal value to such shares. Accordingly, Dr. Kalayoglu may be deemed to have sole voting and dispositive power of the shares of Common Stock and Series A Preferred Stock held by the Trust. The ability of the shares of Series A Preferred Stock held by the Trust to convert into shares of Common Stock is subject to a beneficial ownership limitation, such that neither the Trust may convert shares of Series A Preferred Stock into Common Stock to the extent that doing so would result in Dr. Kalayoglu or the Trust beneficially owning greater than 19.9% of the Company’s outstanding Common Stock after giving effect to such conversion. |

19

TABLE OF CONTENTS

Relationship with the Selling Stockholders 2024 Private Placement Dr. Timothy A. Springer, TAS, and Dr. Springer’s spouse, Dr. Chafen Lu, purchased shares of our Series B Preferred Stock in a private placement, which closed on July 3, 2024, or the 2024 Private Placement. The following table sets forth the number of shares of Series B Preferred Stock purchased in the 2024 Private Placement by such parties:

| Name                                                       |     | Shares of Series B Preferred 
              Stock Purchased |     |